Zoetis (ZTS) Stock Rating Lowered by Zacks Investment Research
Zacks Investment Research downgraded shares of Zoetis (NYSE:ZTS) from a hold rating to a sell rating in a research report report published on Saturday morning. They currently have $83.00 price target on the stock.
According to Zacks, “Zoetis faces stiff competition from other animal health medicines and vaccines companies like Merck Animal Health (the animal health division of Merck), Elanco (the animal health division of Eli Lilly), Bayer Animal Health (the animal health division of Bayer) and Boehringer Ingelheim Animal Health (the animal health division of Boehringer Ingelheim). Disease outbreak among animals is a material cause of concern for Zoetis’ livestock products.In addition, companion animal health products are often directly prescribed and dispensed by veterinarians. The swine business is being impacted by competition for Fostera. These competitive pressures could adversely affect the company’s business and operating results. However, shares of the company have outperformed the industry in the last six months.”
A number of other equities research analysts also recently weighed in on ZTS. BMO Capital Markets boosted their price objective on shares of Zoetis to $78.00 and gave the company a market perform rating in a research report on Tuesday, January 9th. Cantor Fitzgerald set a $85.00 price objective on shares of Zoetis and gave the company a buy rating in a research report on Thursday, January 11th. Citigroup raised shares of Zoetis from a neutral rating to a buy rating and set a $85.00 price objective for the company in a research report on Thursday, January 4th. Craig Hallum reaffirmed a buy rating and set a $85.00 price objective (up previously from $77.00) on shares of Zoetis in a research report on Tuesday, January 2nd. Finally, Morgan Stanley raised shares of Zoetis from an equal weight rating to an overweight rating and set a $80.00 price objective for the company in a research report on Wednesday, November 29th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $71.94.
Shares of Zoetis (NYSE ZTS) opened at $75.39 on Friday. The firm has a market cap of $36,740.00, a PE ratio of 39.68, a PEG ratio of 1.90 and a beta of 1.06. Zoetis has a 1 year low of $52.00 and a 1 year high of $75.69. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The company’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.52 EPS. equities research analysts forecast that Zoetis will post 2.37 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be paid a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a yield of 0.67%. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. Zoetis’s payout ratio is presently 22.11%.
A number of institutional investors have recently bought and sold shares of the business. Wilbanks Smith & Thomas Asset Management LLC boosted its stake in Zoetis by 1.8% during the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock valued at $354,000 after purchasing an additional 98 shares during the period. Scotia Capital Inc. boosted its stake in Zoetis by 1.5% during the 2nd quarter. Scotia Capital Inc. now owns 9,628 shares of the company’s stock valued at $601,000 after purchasing an additional 142 shares during the period. Nordea Investment Management AB lifted its stake in shares of Zoetis by 0.7% in the 2nd quarter. Nordea Investment Management AB now owns 24,854 shares of the company’s stock worth $1,550,000 after acquiring an additional 169 shares during the period. Moors & Cabot Inc. lifted its stake in shares of Zoetis by 1.1% in the 2nd quarter. Moors & Cabot Inc. now owns 14,969 shares of the company’s stock worth $929,000 after acquiring an additional 170 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after acquiring an additional 230 shares during the period. 93.14% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/zoetis-zts-stock-rating-lowered-by-zacks-investment-research/1808778.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with Analyst Ratings Network's FREE daily email newsletter.